Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status Read more about Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With Renal Cell Carcinoma (RCC) Read more about ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With Renal Cell Carcinoma (RCC)
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Read more about Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
VasQ External Support for Arteriovenous Fistula Read more about VasQ External Support for Arteriovenous Fistula
Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery Read more about Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer Read more about Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Read more about A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed Read more about Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery Read more about Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) Read more about Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)